Ayyildiz O.Şit D.Söker M.Kadiro?lu A.K.Yeşilba?dan A.H.2024-04-242024-04-2420051306-133Xhttps://hdl.handle.net/11468/23987Daunorubicin is used widely in the treatment of acute myeloblastic leukemia (AML). Daunorubicin has some toxicity which limit the usage of drug. Blue-gray pigmentation is an uncommon side effect of daunorubicin. It is one of the side effect which might disturb patient for a long time cosmetically. We report here a hyperpigmentation case with acute myelomonocytic leukemia who is still on the treatment.trinfo:eu-repo/semantics/closedAccessBlue-Gray PigmentationDaunorubicinDaunorubicin induced blue-gray hyperpigmentation: A case reportDaunorubicin induced blue-gray hyperpigmentation: A case reportDaunorubisin'e ba?li blue-gray hiperpigmentasyon: Bir olgu sunumuDaunorubisin'e ba?li blue-gray hiperpigmentasyon: Bir olgu sunumuArticle1531491522-s2.0-33646480217Q4